Nuvalent
NUVL----
Nuvalent (NUVL)
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zi...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Nuvalent Analyst Rating
View MoreForecast & Rating
Jun 24, 2026Price forecast
$125.130.94%
Forecast & RatingHold
17analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 1 day ago, 07:06 AM
Citigroup Reiterates "Neutral" Rating for GSK (NYSE:GSK)
- PharmaTimes · 2 days ago, 02:49 AM
GSK wins US approval for ROS1 lung cancer therapy
- StockTitan · Jul 22 at 04:58 AM
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer | GSK Stock News
- Market Beat · Jul 20 at 01:14 AM
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Rating of "Hold" from Analysts
- PUBT · Jul 15 at 08:04 AM
Nuvalent seeks Nasdaq delisting, plans to end SEC reporting after merger closes
- Tip Ranks · Jul 15 at 07:42 AM
GSK Pays $10.6 Billion for Nuvalent to Accelerate Lung Cancer Push
